Cirius Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://ciriustx.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
Phase 3
Not yet recruiting
- Conditions
- Type2 DiabetesNASH - Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNon-Alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Cirius Therapeutics, Inc.
- Target Recruit Count
- 1800
- Registration Number
- NCT03970031
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Cirius Therapeutics, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT02784444
News
No news found